

Wei-Yu Liao

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/661854/wei-yu-liao-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

1,705
citations

25
h-index

39
g-index

62
ext. papers

2,033
ext. citations

5.1
avg, IF

4.43
L-index

#	Paper	IF	Citations
60	The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211018022	5.4	0
59	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100140	1.4	2
58	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100099	1.4	
57	Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer. <i>Nephrology</i> , 2020 , 25, 730	2.2	0
56	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020 , 25, 702-711	5.7	11
55	Autophagy in fibroblasts induced by cigarette smoke extract promotes invasion in lung cancer cells. <i>International Journal of Cancer</i> , 2020 , 147, 2587-2596	7.5	9
54	Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 50-61	8.9	29
53	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. <i>European Journal of Cancer</i> , 2020 , 124, 110-122	7.5	28
52	Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2019 , 15, 115-118	3.1	1
51	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2019 , 117, 107-115	7.5	18
50	Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. <i>Oncologist</i> , 2019 , 24, e1417-e1423	5.7	13
49	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. <i>International Journal of Cancer</i> , 2019 , 144, 2887-2896	7.5	32
48	Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2018 , 19, e361-e372	4.9	14
47	Trajectories of caregiver burden and related factors in family caregivers of patients with lung cancer. <i>Psycho-Oncology</i> , 2018 , 27, 1493-1500	3.9	16
46	The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. <i>Scientific Reports</i> , 2018 , 8, 5837	4.9	10
45	Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. <i>Lung Cancer</i> , 2018 , 118, 90-96	5.9	6
44	Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , 2018 , 126, 368-374	5.3	17

43	Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study. <i>Supportive Care in Cancer</i> , 2018 , 26, 989-996	3.9	13
42	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018 , 9, 1813-1820	4.5	34
41	Prognostic factors of afatinib as a first-line therapy for advanced mutation-positive lung adenocarcinoma: a real-world, large cohort study. <i>Oncotarget</i> , 2018 , 9, 23749-23760	3.3	14
40	Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 107-116	35.1	86
39	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1897-1905	8.9	45
38	Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?. <i>European Journal of Cancer</i> , 2018 , 103, 32-40	7.5	9
37	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. <i>Oncologist</i> , 2017 , 22, 1075-1083	5.7	19
36	Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 567-572	8.9	139
35	Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study. <i>Lung Cancer</i> , 2017 , 104, 58-64	5.9	18
34	EGFR mutation and lobar location of lung adenocarcinoma. <i>Carcinogenesis</i> , 2016 , 37, 157-162	4.6	10
33	Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016 , 94, 46-53	5.9	48
32	The unmet supportive care needs-what advanced lung cancer patients/caregivers need and related factors. <i>Supportive Care in Cancer</i> , 2016 , 24, 2999-3009	3.9	39
31	Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases. <i>PLoS ONE</i> , 2016 , 11, e0153938	3.7	6
30	GM2-activator protein: a new biomarker for lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 102-9	8.9	11
29	Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e58-60	8.9	12
28	Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer. <i>Journal of Pathology</i> , 2015 , 235, 50-64	9.4	16
27	Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. <i>PLoS ONE</i> , 2015 , 10, e0120852	3.7	58
26	Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014 , 7, 799-805	4.4	12

25	Modulating chemotaxis of lung cancer cells by using electric fields in a microfluidic device. <i>Biomicrofluidics</i> , 2014 , 8, 024107	3.2	14
24	Quality of life and related factors in patients with newly diagnosed advanced lung cancer: a longitudinal study. <i>Oncology Nursing Forum</i> , 2014 , 41, E44-55	1.7	34
23	A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19013-e19013	2.2	1
22	Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. <i>Lung Cancer</i> , 2013 , 82, 420-5	5.9	32
21	Survival of lung adenocarcinoma patients with malignant pleural effusion. <i>European Respiratory Journal</i> , 2013 , 41, 1409-18	13.6	68
20	Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 418-24	4.9	17
19	Interaction between lung cancer cell and myofibroblast influenced by cyclic tensile strain. <i>Lab on A Chip</i> , 2013 , 13, 1114-20	7.2	18
18	Anxiety, depression and related factors in family caregivers of newly diagnosed lung cancer patients before first treatment. <i>Psycho-Oncology</i> , 2013 , 22, 2617-23	3.9	35
17	The migration speed of cancer cells influenced by macrophages and myofibroblasts co-cultured in a microfluidic chip. <i>Integrative Biology (United Kingdom)</i> , 2012 , 4, 177-82	3.7	32
16	Risk factors of pneumothorax after endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions. <i>PLoS ONE</i> , 2012 , 7, e49125	3.7	20
15	Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 973-81	8.9	49
14	Endobronchial ultrasound-guided transbronchial biopsy of peripheral pulmonary lesions: how many specimens are necessary?. <i>Respiration</i> , 2012 , 84, 128-34	3.7	18
13	Analysis of the paracrine loop between cancer cells and fibroblasts using a microfluidic chip. <i>Lab on A Chip</i> , 2011 , 11, 1808-14	7.2	44
12	Symptoms, psychological distress, and supportive care needs in lung cancer patients. <i>Supportive Care in Cancer</i> , 2011 , 19, 1743-51	3.9	68
11	Label-free quantification of asymmetric cancer-cell filopodium activities in a multi-gradient chip. <i>Lab on A Chip</i> , 2009 , 9, 884-90	7.2	9
10	Emphysematous gastritis: a deadly infectious disease. <i>Scandinavian Journal of Infectious Diseases</i> , 2009 , 41, 317-9		18
9	TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 763-70	10.2	102
8	Dynamics of cancer cell filopodia characterized by super-resolution bright-field optical microscopy. <i>Optics Express</i> , 2007 , 15, 76-82	3.3	8

7	Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. <i>Respiratory Research</i> , 2005 , 6, 89	7.3	20
6	Autocrine and paracrine regulation of interleukin-8 expression in lung cancer cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2005 , 32, 540-7	5.7	34
5	Testing the functional status model in patients with chronic obstructive pulmonary disease. <i>Journal of Advanced Nursing</i> , 2004 , 48, 342-50	3.1	26
4	The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. <i>Lung Cancer</i> , 2004 , 44, 149-57	5.9	77
3	Pneumothorax in the ICU: patient outcomes and prognostic factors. <i>Chest</i> , 2002 , 122, 678-83	5.3	58
2	US-guided transthoracic cutting biopsy for peripheral thoracic lesions less than 3 cm in diameter. <i>Radiology</i> , 2000 , 217, 685-91	20.5	78
1	Bacteriology of infected cavitating lung tumor. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000 , 161, 1750-3	10.2	30